drugset / Trial / NCT04476043
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. All eligible participants will be invited to continue treatment for an additional 48-week Long-term extension period (also open label).
Timeline
- Start
- 2020-08-25
- Primary completion
- 2021-12-15
- Completion
- 2023-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Povorcitinib | Small molecule | 15 mg | Oral |
| Subject | Povorcitinib | Small molecule | 45 mg | Oral |
| Subject | Povorcitinib | Small molecule | 75 mg | Oral |